Secondary Progressive Multiple Sclerosis (SPMS): Diagnosis, Symptoms & Therapy

SPMS follows relapsing-remitting MS (RRMS), marked by steady neurological worsening independent of relapses. ~50% of RRMS patients transition within 10–20 years.

Clinical Features

  • Gradual accumulation of disability (EDSS increase).
  • Pyramidal signs: weakness, spasticity, hyperreflexia.
  • Cerebellar: ataxia, intention tremor.
  • Sensory: numbness, paresthesia.
  • Bladder/bowel dysfunction, cognitive decline, fatigue, depression.

Diagnosis

Clinical: ≥6 months of progressive worsening without relapses (or with overlapping relapses = active SPMS). Supported by MRI (new T2 lesions, atrophy) and CSF (oligoclonal bands).

Disease-Modifying Therapies (DMTs)

  • Active SPMS (with relapses/new MRI activity): Siponimod, ozanimod, cladribine, alemtuzumab, natalizumab, anti-CD20 (ocrelizumab, ofatumumab).
  • Non-active SPMS: Limited options; siponimod approved based on EXPAND trial showing disability slowing.

Rehabilitation & Supportive Care

  • Physical/occupational/speech therapy for function maintenance.
  • Assistive devices (cane, walker, wheelchair).
  • Symptom management: spasticity (baclofen, botox), neuropathic pain, bladder issues.
  • Psychosocial: counseling, support groups, vocational rehab.

Early SPMS recognition enables timely DMT initiation to preserve independence.

Multiple Sclerosis - Related Articles